MTOR and hepatocellular carcinoma: Since clinical evidence was provided on the efficacy of combined mTOR inhibitors and PD-1/PD-L1-blocking agents in HCC and metastatic renal cell carcinoma34,35, copanlisib could be used in combination with immune checkpoint inhibitors to potentiate the effect of these agents.